GM-CSF-induced autoimmune gastritis in interferon α receptor deficient mice

Journal of Autoimmunity

Volumn 31, Issue 3, 2008, Pages 274-280

  Field, Judith ^a   Alderuccio, Frank ^b   Hertzog, Paul ^c   Toh, Ban Hock ^a  

^a Department of Medicine   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Experimental autoimmune gastritis; Gastric H K ATPase; Granulocyte monocyte colony stimulating factor; Interferon receptor (IFNAR) 2; Type I interferon

Indexed keywords

ALPHA INTERFERON RECEPTOR; AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; GASTRITIS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSGENIC MOUSE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; GASTRITIS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, TRANSGENIC; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 56349085997     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.04.003     Document Type: Article

References (79)

1. Hertzog P., Hwang S.Y., Holland K.A., Tymms M.J., Iannelo R., and Kola I. A gene of human chromosome 21 located in the region 21q22.2 to 22q22.3 encodes a factor necessary to signal transduction and antiviral responses of type I interferons. J Biol Chem 269 (1994) 14088-14093
2. LaFleur D.W., Nardelli B., Tsareva T., Mather D., Feng P., Semenuk, et al. Interferon-K, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276 (2001) 39765-39771
3. Kenji O., Kincade P.W., Zhang C., Tomiyama Y., and Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 12 (2001) 337-348
4. Pestka S., Langer J.A., Zoon K.C., and Samuel C.E. Interferons and their actions. Annu Rev Biochem 56 (1987) 727-777
5. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
6. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 (2003) 69-77
7. Ozato K., Tsujimura H., and Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune System. Biotechniques Suppl (2002) 66-72
8. Colonna M., Krug A., and Cella M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 14 (2002) 373-379
9. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
10. Ogasawara K., Hida S., Weng Y., Saiura A., Sato K., Takayanagi H., et al. Requirement of the IFN-alpha/beta-induced Cxcr3 chemokine signalling for Cd8+ T cell activation. Genes Cells 7 (2002) 309-320
11. Marrack P., Kappler J., and Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 189 (1999) 521-530
12. Zhang X., Sun S., Hwang I., Tough D.F., and Sprent J. Potent and selective stimulation of memory-phenotype Cd8+ T cells in vivo by IL-15. Immunity 8 (1998) 591-599
13. Tough D.F., Borrow P., and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
14. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
15. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., et al. Critical role for Stat4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297 (2002) 2063-2066
16. Biron C.A. Interferons alpha and beta as immune regulators - a new look. Immunity 14 (2001) 661-664
17. Mitani Y., Takaoka A., Kim S.H., Kato Y., Yokochi T., Tanaka N., et al. Cross talk of the interferon-alpha/beta signalling complex with Gp130 for effective interleukin-6 signalling. Genes Cells 6 (2001) 631-640
18. Brassard D.L., Grace M.J., and Bordens R.W. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71 (2002) 565-581
19. Dickensheets H.L., Venkataraman C., Schindler U., and Donnelly R.P. Interferons inhibit activation of Stat6 by interleukin 4 in human monocytes by inducing Socs-1 gene expression. Proc Natl Acad Sci U S A 96 (1999) 10800-10805
20. Sharif M.N., Tassiulas I., Hu Y., Mecklenbrauker I., Tarakhovsky A., and Ivashkiv L.B. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172 (2004) 6476-6481
21. Hardy M.P., Hertzog P.J., and Owczarek C.M. Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression. Biochem J 365 (2002) 355-367
22. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23 (2005) 307-336
23. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 (2003) 711-723
24. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100 (2003) 2610-2615
25. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 92 (1995) 11284-11288
26. Hron J.D., and Peng S.L. Type I IFN protects against murine lupus. J Immunol 173 (2004) 2134-2142
27. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197 (2003) 777-788
28. Braun D., Geraldes P., and Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20 (2003) 15-25
29. Pfeffer L.M., Basu L., Pfeffer S.R., Yang C.H., Murti A., Russell-Harde D., et al. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem 272 (1997) 11002-11005
30. Fenner J.E., Starr R., Cornish A.L., Zhang J.G., Metcalf D., Schreiber R.D., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7 (2006) 33-39
31. de Weerd N, Gould J, Fenner JE, Scott B, Hertzog P. Structural basis of the differential proinflammatory signaling of type I interferons through Ifnar1 and Ifnar2 receptors. 7th World Congress on Inflammation 2005.
32. Toh B.H., and Alderuccio F. Pernicious anaemia. Autoimmunity 37 (2004) 357-361
33. Toh B.H., van Driel I.R., and Gleeson P.A. Pernicious anemia. N Engl J Med 337 (1997) 1441-1448
34. D'Elios M.M., Amedei A., Azzurri A., Benagiano M., Del Prete G., Bergman M.P., et al. Molecular specificity and functional properties of autoreactive T cell response in human gastris autoimmunity. Int Rev Immunol (2005) 111-122
35. D'Elios M.M., Bergman M.P., Azzurri A., Amedei A., Benagiano M., De Pont J.J., et al. H(+),K(+)-ATPase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 120 (2001) 377-386
36. Gleeson P.A., and Toh B.H. Molecular targets in pernicious anaemia. Immunol Today 12 (1991) 233-238
37. Irvine W.J., Davies S.H., Haynes R.C., and Scarth L. Secretion of intrinsic factor in response to histamine and to gastrin in the diagnosis of addisonian pernicious anemia. Lancet 15 (1965) 397-401
38. Taylor K.B., Roitt I.M., Doniach D., Couchman K.G., and Shapland C. Autoimmune phenomena in pernicious anaemia: gastric antibodies. BMJ 5316 (1962) 1347-1352
39. Field J., Biondo M., Murphy K., Alderuccio F., and Toh B.H. Experimental autoimmune gastritis: mouse models of human organ-specific autoimmune disease. Int Rev Immunol 24 (2005) 93-110
40. Biondo M., Nasa Z., Marshall A., Toh B.H., and Alderuccio F. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J Immunol 166 (2001) 2090-2099
41. Alderuccio F., Toh B.H., Tan S.S., Gleeson P.A., and van Driel I.R. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J Exp Med 178 (1993) 419-426
42. Peterson K.S., Huang J.F., Zhu J., D'Agati V., Liu X., Miller N., et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 113 (2004) 1722-1733
43. Vassileva G., Chen S.C., Zeng M., Abbondanzo S., Jensen K., Gorman D., et al. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. J Immunol 170 (2003) 5748-5755
44. Hasegawa K., and Hayashi T. Synthetic Cpg oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus 12 (2003) 838-845
45. Crow M.K. Interferon-alpha: a new target for therapy in systemic lupus erythematosus?. Arthritis Rheum 48 (2003) 2396-2401
46. Gota C., and Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36 (2003) 511-518
47. Han G.M., Chen S.L., Shen N., Ye S., Bao C.D., and Gu Y.Y. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 4 (2003) 177-186
48. Alcorta D., Preston G., Munger W., Sullivan P., Yang J.J., Waga I., et al. Microarray studies of gene expression in circulating leukocytes in kidney diseases. Exp Nephrol 10 (2002) 139-149
49. Ronnblom L., and Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22 (2001) 427-431
50. Pelegrin M., Devedjian J.C., Costa C., Visa J., Solanes G., Pujol A., et al. Evidence from transgenic mice that interferon-beta may be involved in the onset of diabetes mellitus. J Biol Chem 273 (1998) 12332-12340
51. Wloch M.K., Alexander A.L., Pippen A.M., Pisetsky D.S., and Gilkeson G.S. Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. J Immunol 158 (1997) 4500-4506
52. Stewart F.M., Crittenden R.B., Lowry P.A., Pearson-White S., and Quesenberry P.J. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 81 (1993) 2566-2571
53. Ewel C.H., Sobel D.O., Zeligs B.J., and Bellanti J.A. Poly I:C accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes 41 (1992) 1016-1021
54. Giron D.J., Agostini H.J., and Thomas D.C. Effect of interferons and Poly(I):Poly(C) on the pathogenesis of the diabetogenic variant of encephalomyocarditis virus in different mouse strains. J Interferon Res 8 (1988) 745-753
55. Heremans H., Billiau A., Colombatti A., Hilgers J., and de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 21 (1978) 925-930
56. Hafler D.A. Multiple sclerosis. J Clin Invest 113 (2004) 788-794
57. Tanaka-Kataoka M., Kunikata T., Takayama S., Iwaki K., Fujii M., Ohashi K., et al. Oral use of interferon-alpha delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. J Interferon Cytokine Res 19 (1999) 877-879
58. Sobel D.O., and Ahvazi B. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes 47 (1998) 1867-1872
59. Sobel D.O., Creswell K., Yoon J.W., and Holterman D. Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Sci 62 (1998) 1293-1302
60. Sobel D.O., Goyal D., Ahvazi B., Yoon J.W., Chung Y.H., Bagg A., et al. Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J Autoimmun 11 (1998) 343-352
61. Serreze D.V., Hamaguchi K., and Leiter E.H. Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 2 (1989) 759-776
62. Crow M.K., and Kirou K.A. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16 (2004) 541-547
63. Devendra D., and Eisenbarth G.S. Interferon alpha - a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 111 (2004) 225-233
64. Huang X., Yuang J., Goddard A., Foulis A.K., James R.F., Lernmark A., et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44 (1995) 658
65. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., and Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 (1979) 5
66. Wesche B., Jaeckel E., Trautwein C., Wedemeyer H., Falorni A., Frank H., et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 48 (2001) 378-383
67. Kado S., Miyamoto J., Komatsu N., Iwaki Y., Ozaki H., Taguchi H., et al. Type 1 diabetes mellitus caused by treatment with interferon-β. Int Med 39 (2000) 146-149
68. Chung Y.H., and Shong Y.K. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol 88 (1993) 244-247
69. Chakrabarti D., Hultgren B., and Stewart T.A. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 157 (1996) 522-528
70. Alba A., Puertas M.C., Carrillo J., Planas R., Ampudia R., Pastor X., et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol 173 (2004) 6667-6675
71. O'Gorman M.R., Oger J., and Kastrukoff L.F. Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients. Clin Exp Immunol 67 (1987) 66-75
72. Jacobs L., O'Malley J., Freeman A., and Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214 (1981) 1026-1028
73. Shenoy M., Baron S., Wu B., Goluszko E., and Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol 154 (1995) 6203-6208
74. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4 (2003) 471-477
75. Akbar A.N., Lord J.M., and Salmon M. IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol Today 21 (2000) 337-342
76. Marshall A.C., Toh B.H., and Alderuccio F. Tumor necrosis factor alpha is not implicated in the genesis of experimental autoimmune gastritis. J Autoimmun 22 (2004) 1-11
77. Field J., Marshall A.C., Hertzog P.J., Wells T.N., Alderuccio F., and Toh B.H. Chemokine receptor CCR5 is not required for development of experimental autoimmune gastritis. Clin Immunol 109 (2003) 238-247
78. Martinelli T.M., van Driel I.R., Alderuccio F., Gleeson P.A., and Toh B.H. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology 110 (1996) 1791-1802
79. Alderuccio F., Biondo M., and Toh B.H. Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice. Autoimmunity 35 (2002) 67-73